title: Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
abstract: The efficacy of thermochemotherapy in adult patients with primary, recurrent or inadequately resected non-metastatic high-risk soft-tissue sarcomas (STS) was assessed. 54 patients were prospectively treated with four cycles of etoposide, ifosfamide and doxorubicin (EIA) combined with regional hyperthermia (RHT) followed by surgery, another four cycles of EIA without RHT and external beam radiation. The objective response rate was 16% and at a median follow-up time of 57 months, the 4-year estimated rates of local failure-free survival (LFFS), distant metastasis-free survival (DMFS), event-free survival (EFS) and overall survival (OS) were 59% (95% confidence interval (CI) 45-73%), 59% (95% CI 44-73%), 26% (95% CI 14-38%) and 40% (95% CI 27-53%), respectively. OS was in favour of patients responding to neoadjuvant treatment (P=0.073). In comparison to a preceding phase II study including pre- and postsurgical thermochemotherapy (RHT-91), at a 4-year follow-up the RHT-95 study cohort showed an inferior LFFS rate (P=0.027), but this did not affect DMFS (P=0.558) or OS (P=0.126). Hence, postsurgical thermochemotherapy seems critical for local tumour control without affecting survival.
authors.affiliation: Department of Internal Medicine III, Klinikum Grosshadern Medical Center (KGMC), Ludwig-Maximilians-University, D-81377, Munich, Germany. clemens.wendtner@med3.med.uni-muenchen.de
authors.forename: C
authors.initials: C
authors.lastname: Wendtner
authors.forename: S
authors.initials: S
authors.lastname: Abdel-Rahman
authors.forename: J
authors.initials: J
authors.lastname: Baumert
authors.forename: M H
authors.initials: MH
authors.lastname: Falk
authors.forename: M
authors.initials: M
authors.lastname: Krych
authors.forename: M
authors.initials: M
authors.lastname: Santl
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: R D
authors.initials: RD
authors.lastname: Issels
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015331:Cohort Studies; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010865:Pilot Projects; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant / Q000379:methods; D012307:Risk Factors; D012509:Sarcoma / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D004317:Doxorubicin; D007069:Ifosfamide